Politico December 8, 2023
Carmen Paun, Erin Schumaker, Evan Peng, Daniel Payne and Ruth Reader

Pharmaceutical companies and medical device manufacturers expect artificial intelligence to have a profound impact on their businesses next year and are already experimenting with it, according to a Deloitte Center for Health Solutions survey of some 120 executives.

Drug and device makers are exploring how advanced AI could automate repetitive functions, reimagine supply chains and support compliance and regulatory affairs, according to Deloitte.

Who’s in charge? About a quarter of the pharma executives responding to the survey said they have established governance and oversight for AI and another half said they were expecting to do it over the next year.

Medical device manufacturers are slightly behind: One in 5 respondents from the industry said they have a governance and oversight...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Medical Devices, Pharma, Pharma / Biotech, Technology
Drugmakers counter HHS' first offers in Medicare price talks
Pfizer stops buildout of $350M Seagen plant, leaving 120 workers' roles in question
Walgreens CEO: Shields Specialty Pharmacy Key To Growth And Won’t Be Sold
ARPA-H behind on duplicative research efforts, GAO says
Retail pharmacies to begin selling OTC birth control within weeks

Share This Article